Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recilisib

Next Previous
Drug Profile

Recilisib

Alternative Names: Ex-RAD; ON 01210.Na; ON-01210; ON-01210-Na; Recilisib sodium

Latest Information Update: 21 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onconova Therapeutics
  • Class Radioprotectives; Small molecules; Sulfonamides
  • Mechanism of Action Apoptosis inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Acute radiation syndrome

Most Recent Events

  • 21 May 2018 Recilisib is still in phase I trials for Acute Radiation Syndrome in USA (PO) (SC) (Onconova Therapeutics pipeline, May-2018)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Acute-radiation-syndrome in USA (PO, Liquid)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Acute-radiation-syndrome in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top